COMPANY

TrueBinding

Keywords: neurology Alzheimer's Disease Alzheimer Disease Parkinson's Disease Acute Ischemic Stroke Covid19 TB006

Location: Santa Clara, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Mar 20, 2025 Trial start 2: A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease source ↗
Sep 15, 2022 Trial start Phase 2: A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease source ↗
Jul 26, 2022 Trial start Phase 2: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke source ↗
Oct 8, 2021 Trial start Phase 1/Phase 2: Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease source ↗
Jun 1, 2021 Trial start Phase 1: Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects source ↗
Jun 1, 2021 Trial start Phase 1: Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19 source ↗

Nov 28, 2026 (ESTIMATED) · 2 · A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease · NCT06773962

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05476783	A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease	Phase 2	Terminated	Sep 15, 2022	Nov 17, 2023 (actual)
NCT06773962	A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease	2	Active, not recruiting	Mar 20, 2025	Nov 28, 2026 (estimated)
NCT05959239	TB006 Expanded Access (EA) Compassionate Use	Not listed	Available	Not listed	Not listed
NCT04920786	Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects	Phase 1	Completed	Jun 1, 2021	May 3, 2022 (actual)
NCT05156827	A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke	Phase 2	Withdrawn	Jul 26, 2022	Dec 18, 2023 (actual)
NCT05074498	Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease	Phase 1/Phase 2	Completed	Oct 8, 2021	Oct 13, 2022 (actual)
NCT04801056	Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19	Phase 1	Withdrawn	Jun 1, 2021	Sep 1, 2021 (actual)